{"id":"https://openalex.org/W2082425581","doi":"https://doi.org/10.1097/bor.0b013e3283521c4e","title":"Immunogenicity of biological therapeutics: from assay to patient","display_name":"Immunogenicity of biological therapeutics: from assay to patient","alternate_titles":[],"publication_year":2012,"publication_date":"2012-03-04","ids":{"openalex":"https://openalex.org/W2082425581","doi":"https://doi.org/10.1097/bor.0b013e3283521c4e","mag":"2082425581","pmid":"https://pubmed.ncbi.nlm.nih.gov/22388644"},"language":"en","primary_location":{"id":"doi:10.1097/bor.0b013e3283521c4e","doi":"https://doi.org/10.1097/bor.0b013e3283521c4e","is_oa":false,"landing_page_url":"https://doi.org/10.1097/bor.0b013e3283521c4e","pdf_url":null,"source":{"id":"https://openalex.org/S31702427","display_name":"Current Opinion in Rheumatology","issn_l":"1040-8711","issn":["1040-8711","1080-8175","1531-6963"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Opinion in Rheumatology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2082425581"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017243329","display_name":"Charlotte L M Krieckaert","orcid":"https://orcid.org/0000-0001-6591-7838","observed_orcids":["https://orcid.org/0000-0001-6591-7838"]},"institutions":[{"id":"https://openalex.org/I4210091224","display_name":"Reade","ror":"https://ror.org/00bp9f906","country_code":"NL","type":"facility","lineage":["https://openalex.org/I4210091224"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Charlotte Krieckaert","raw_affiliation_strings":["Jan van Breemen Research Institute/Reade, Amsterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jan van Breemen Research Institute/Reade, Amsterdam, The Netherlands","institution_ids":["https://openalex.org/I4210091224"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050087953","display_name":"Theo Rispens","orcid":"https://orcid.org/0000-0001-9600-1312","observed_orcids":["https://orcid.org/0000-0001-9600-1312"]},"institutions":[{"id":"https://openalex.org/I3020210244","display_name":"Sanquin","ror":"https://ror.org/01fm2fv39","country_code":"NL","type":"nonprofit","lineage":["https://openalex.org/I3020210244"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Theo Rispens","raw_affiliation_strings":["Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands","institution_ids":["https://openalex.org/I3020210244"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5029733252","display_name":"Gertjan Wolbink","orcid":"https://orcid.org/0000-0003-1924-7460","observed_orcids":["https://orcid.org/0000-0003-1924-7460"]},"institutions":[{"id":"https://openalex.org/I3020210244","display_name":"Sanquin","ror":"https://ror.org/01fm2fv39","country_code":"NL","type":"nonprofit","lineage":["https://openalex.org/I3020210244"]},{"id":"https://openalex.org/I4210091224","display_name":"Reade","ror":"https://ror.org/00bp9f906","country_code":"NL","type":"facility","lineage":["https://openalex.org/I4210091224"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Gertjan Wolbink","raw_affiliation_strings":["Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands","Jan van Breemen Research Institute/Reade","to Gertjan Wolbink, Jan van Breemen Research Institute/Reade, dr Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands. Tel: +31205896589; e-mail: [email\u00a0protected]","e-mail: [email\u00a0protected]","to Gertjan Wolbink, Jan van Breemen Research Institute/Reade, dr Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands. Tel: +31205896589"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands","institution_ids":["https://openalex.org/I3020210244"]},{"raw_affiliation_string":"Jan van Breemen Research Institute/Reade","institution_ids":["https://openalex.org/I4210091224"]},{"raw_affiliation_string":"to Gertjan Wolbink, Jan van Breemen Research Institute/Reade, dr Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands. Tel: +31205896589; e-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I4210091224"]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"to Gertjan Wolbink, Jan van Breemen Research Institute/Reade, dr Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands. Tel: +31205896589","institution_ids":["https://openalex.org/I4210091224"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5029733252"],"corresponding_institution_ids":["https://openalex.org/I3020210244","https://openalex.org/I4210091224"],"apc_list":null,"apc_paid":null,"fwci":0.6804,"has_fulltext":false,"cited_by_count":77,"citation_normalized_percentile":{"value":0.57157785,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"24","issue":"3","first_page":"306","last_page":"311"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10373","display_name":"Renal Transplantation Outcomes and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2747","display_name":"Transplantation"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.9860000014305115},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.9959999918937683},{"id":"https://openalex.org/keywords/antidrug-antibodies","display_name":"antidrug antibodies","score":0.9129999876022339},{"id":"https://openalex.org/keywords/drug-interference","display_name":"drug interference","score":0.6230000257492065},{"id":"https://openalex.org/keywords/methotrexate","display_name":"methotrexate","score":0.9300000071525574},{"id":"https://openalex.org/keywords/therapeutic-drug-monitoring","display_name":"therapeutic drug monitoring","score":0.8700000047683716},{"id":"https://openalex.org/keywords/personalized-medicine","display_name":"personalized medicine","score":0.843999981880188},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7480000257492065},{"id":"https://openalex.org/keywords/rheumatic-diseases","display_name":"rheumatic diseases","score":0.5360000133514404}],"concepts":[{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.9806531667709351},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8059048652648926},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5131459832191467},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4666234254837036},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.43074917793273926},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.42625513672828674},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4206472337245941},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.39779266715049744},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.15823960304260254}],"mesh":[{"descriptor_ui":"D001688","descriptor_name":"Biological Products","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001688","descriptor_name":"Biological Products","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D001688","descriptor_name":"Biological Products","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007118","descriptor_name":"Immunoassay","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D007136","descriptor_name":"Immunoglobulins","qualifier_ui":"Q000096","qualifier_name":"biosynthesis","is_major_topic":false},{"descriptor_ui":"D007136","descriptor_name":"Immunoglobulins","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D015986","descriptor_name":"Confounding Factors, Epidemiologic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016903","descriptor_name":"Drug Monitoring","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1097/bor.0b013e3283521c4e","doi":"https://doi.org/10.1097/bor.0b013e3283521c4e","is_oa":false,"landing_page_url":"https://doi.org/10.1097/bor.0b013e3283521c4e","pdf_url":null,"source":{"id":"https://openalex.org/S31702427","display_name":"Current Opinion in Rheumatology","issn_l":"1040-8711","issn":["1040-8711","1080-8175","1531-6963"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Opinion in Rheumatology","raw_type":"journal-article"},{"id":"pmid:22388644","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22388644","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in rheumatology","raw_type":"Journal Article"},{"id":"pmh:oai:pure.amsterdamumc.nl:openaire_cris_publications/341bb9fd-d94a-4311-9b13-9c74c5eebc7b","doi":null,"is_oa":false,"landing_page_url":"https://pure.amsterdamumc.nl/en/publications/341bb9fd-d94a-4311-9b13-9c74c5eebc7b","pdf_url":null,"source":{"id":"https://openalex.org/S7407055222","display_name":"Pure Amsterdam UMC","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Krieckaert, C, Rispens, T & Wolbink, G 2012, 'Immunogenicity of biological therapeutics: from assay to patient', Current opinion in rheumatology, vol. 24, no. 3, pp. 306-311. https://doi.org/10.1097/BOR.0b013e3283521c4e","raw_type":"info:eu-repo/semantics/review"},{"id":"pmh:amcpub:oai:pure.amc.nl:publications/6e8f8b0a-e281-4d6d-972f-7df58dd934ee","doi":null,"is_oa":false,"landing_page_url":"https://pure.amc.nl/en/publications/immunogenicity-of-biological-therapeutics-from-assay-to-patient(6e8f8b0a-e281-4d6d-972f-7df58dd934ee).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306401843","display_name":"Data Archiving and Networked Services (DANS)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1322597698","host_organization_name":"Royal Netherlands Academy of Arts and Sciences","host_organization_lineage":["https://openalex.org/I1322597698"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Current opinion in rheumatology, 24(3), 306 - 311. Lippincott Williams and Wilkins","raw_type":"info:eu-repo/semantics/other"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W1526941119","https://openalex.org/W1964924603","https://openalex.org/W1965832974","https://openalex.org/W1966367484","https://openalex.org/W1978593886","https://openalex.org/W1996522507","https://openalex.org/W1997999969","https://openalex.org/W2000293965","https://openalex.org/W2021590673","https://openalex.org/W2030638063","https://openalex.org/W2031889731","https://openalex.org/W2039804759","https://openalex.org/W2043097326","https://openalex.org/W2047275628","https://openalex.org/W2084986335","https://openalex.org/W2085411350","https://openalex.org/W2094960644","https://openalex.org/W2111046066","https://openalex.org/W2118559127","https://openalex.org/W2123170396","https://openalex.org/W2133832905","https://openalex.org/W2136775453","https://openalex.org/W2140035322","https://openalex.org/W2143649531","https://openalex.org/W2149065814","https://openalex.org/W2159143303","https://openalex.org/W2166771071","https://openalex.org/W2169055269","https://openalex.org/W2169856473","https://openalex.org/W2272291172"],"related_works":["https://openalex.org/W2043097326","https://openalex.org/W2767868064","https://openalex.org/W2325279369","https://openalex.org/W2775894155","https://openalex.org/W3042894437","https://openalex.org/W4307687730","https://openalex.org/W1966367484","https://openalex.org/W2139572080","https://openalex.org/W2752738101","https://openalex.org/W2024710301"],"abstract_inverted_index":{"PURPOSE":[0],"OF":[1],"REVIEW:":[2],"To":[3],"give":[4],"an":[5,72],"overview":[6],"of":[7,17,19,29,36,48,53,92,102,109,115],"the":[8,27,34,37,45,51,90,105,113],"current":[9],"knowledge":[10],"on":[11,44],"assay":[12],"techniques":[13,25],"and":[14,80,97,107],"clinical":[15,46,78],"implications":[16],"immunogenicity":[18,30,49],"biological":[20,41],"therapeutics.":[21,42],"RECENT":[22],"FINDINGS:":[23],"Assay":[24],"for":[26,120],"measurement":[28,91],"have":[31],"improved,":[32],"expanding":[33],"understanding":[35],"immune":[38,74],"response":[39,79],"against":[40],"Knowledge":[43],"effect":[47],"enables":[50],"treatment":[52,128],"patients":[54],"in":[55,126,130],"a":[56,60,131],"targeted":[57],"fashion,":[58],"as":[59],"step":[61],"towards":[62],"personalized":[63],"medicine.":[64],"SUMMARY:":[65],"Biological":[66],"medications":[67],"are":[68],"able":[69],"to":[70],"induce":[71],"antidrug":[73],"response.":[75],"Immunogenicity":[76],"impairs":[77],"is":[81,117],"associated":[82],"with":[83],"adverse":[84],"events.":[85],"Several":[86],"confounding":[87],"factors":[88],"influence":[89],"immunogenicity,":[93],"including":[94],"drug":[95,122],"interference":[96],"background":[98],"problems.":[99],"Concomitant":[100],"administration":[101],"methotrexate":[103],"lowers":[104],"frequency":[106],"amount":[108],"antibodies":[110],"formed,":[111],"whereby":[112],"efficacy":[114],"biologicals":[116],"improved.":[118],"Algorithms":[119],"therapeutic":[121],"monitoring":[123],"could":[124],"aid":[125],"adapting":[127],"strategies":[129],"controlled":[132],"setting.":[133]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2082425581","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":10},{"year":2019,"cited_by_count":9},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":9},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2016-06-24T00:00:00"}
